Blockage of ROS and NF-κB-mediated inflammation by a new chalcone L6H9 protects cardiomyocytes from hyperglycemia-induced injuries

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1852, Issue 7, 2015, Pages 1230-1241

  Zhong, Peng ^a,b   Wu, Lianpin ^c   Qian, Yuanyuan ^a   Fang, Qilu ^a   Liang, Dandan ^a   Wang, Jingying ^a   Zeng, Chunlai ^b   Wang, Yi ^a   Liang, Guang ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b LISHUI CENTRAL HOSPITAL   (China)

^c THE SECOND AFFILIATED HOSPITAL AND YUYING CHILDREN S HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Chalcone derivative; Diabetic cardiomyopathy; Inflammation; NF B; Nrf2; Oxidative stress

Indexed keywords

2,6 DIFLUORO 4' METHOXYCHALCONE; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; CHALCONE DERIVATIVE; CURCUMIN; GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; ANTIOXIDANTS; CHALCONES; NF-KAPPA B; REACTIVE OXYGEN SPECIES;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BODY WEIGHT; CELL PROTECTION; CONTROLLED STUDY; DIABETIC CARDIOMYOPATHY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME INHIBITION; GEL MOBILITY SHIFT ASSAY; GLUCOSE BLOOD LEVEL; HEART HYPERTROPHY; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART PROTECTION; HISTOLOGY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; TRANSCRIPTION INITIATION; TREATMENT DURATION; ANIMALS; CELL LINE; DIABETIC CARDIOMYOPATHIES; DRUG EFFECTS; HYPERGLYCEMIA; METABOLISM; MICE; MICE, INBRED C57BL; MITOCHONDRIA, HEART; MYOCYTES, CARDIAC; PATHOLOGY; RATS;

MUS;

ANIMALS; ANTIOXIDANTS; APOPTOSIS; CELL LINE; CHALCONES; DIABETIC CARDIOMYOPATHIES; HYPERGLYCEMIA; INFLAMMATION; MALE; MICE; MICE, INBRED C57BL; MITOCHONDRIA, HEART; MYOCYTES, CARDIAC; NF-KAPPA B; RATS; REACTIVE OXYGEN SPECIES;

EID: 84925808679     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2015.02.011     Document Type: Article

References (45)

1. Falcão-Pires I., Leite-Moreira A.F. Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatment. Heart Fail. Rev. 2012, 17:325-344.
2. Zhang Y., Sowers J.R., Ren J. Pathophysiological insights into cardiovascular health in metabolic syndrome. Exp. Diabetes Res. 2012, 2012:320534.
3. Boudina S., Abel E.D. Diabetic cardiomyopathy, causes and effects. Rev. Endocr. Metab. Disord. 2010, 11:31-39.
4. Zhou X., Ma L., Habibi J., Whaley-Connell A., Hayden M.R., Tilmon R.D., Brown A.N., Kim J.-A., DeMarco V.G., Sowers J.R. Nebivolol improves diastolic dysfunction and myocardial remodeling through reductions in oxidative stress in the Zucker obese rat. Hypertension 2010, 55:880-888.
5. Booz G.W. Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress. Free Radic. Biol. Med. 2011, 51:1054-1061.
6. Pan Y., Wang Y., Zhao Y., Peng K., Li W., Wang Y., Zhang J., Zhou S., Liu Q., Li X., Cai L., Liang G. Inhibition of JNK phosphorylation by a novel curcumin analog prevents high glucose-induced inflammation and apoptosis in cardiomyocytes and the development of diabetic cardiomyopathy. Diabetes 2014, 63:3497-3511.
7. Batovska D.I., Todorova I.T. Trends in utilization of the pharmacological potential of chalcones. Curr. Clin. Pharmacol. 2010, 5:1-29.
8. Opletalova V., Jahodar L., Jun D., Opletal L. Chalcones (1,3-diarylpropen-1-ones) and their analogs as potential therapeutic agents in cardiovascular system diseases. Ceska a Slovenska farmacie: casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti 2003, 52:12-19.
9. Kontogiorgis C., Mantzanidou M., Hadjipavlou-Litina D. Chalcones and their potential role in inflammation. Mini-Rev. Med. Chem. 2008, 8:1224-1242.
10. Sivakumar P., Prabhakar P., Doble M. Synthesis, antioxidant evaluation, and quantitative structure-activity relationship studies of chalcones. Med. Chem. Res. 2011, 20:482-492.
11. Wu J., Li J., Cai Y., Pan Y., Ye F., Zhang Y., Zhao Y., Yang S., Li X., Liang G. Evaluation and discovery of novel synthetic chalcone derivatives as anti-inflammatory agents. J. Med. Chem. 2011, 54:8110-8123.
12. Yu W., Wu J., Cai F., Xiang J., Zha W., Fan D., Guo S., Ming Z., Liu C. Curcumin alleviates diabetic cardiomyopathy in experimental diabetic rats. PLoS One 2012, 7:e52013.
13. Kumar S., Kain V., Sitasawad S.L. Cardiotoxicity of calmidazolium chloride is attributed to calcium aggravation, oxidative and nitrosative stress, and apoptosis. Free Radic. Biol. Med. 2009, 47:699-709.
14. Singh M., Murthy V., Ramassamy C. Neuroprotective mechanisms of the standardized extract of Bacopa monniera in a paraquat/diquat-mediated acute toxicity. Neurochem. Int. 2013, 62:530-539.
15. Obana M.M.K.M.S.I.T.H.A.Y.T.S.M.K.S.M.A.T.K.M.G.M.M.Y.M.N.H.F.Y. Therapeutic administration of IL-11 exhibits the postconditioning effects against ischemia-reperfusion injury via STAT3 in the heart. Am. J. Physiol. Heart Circ. Physiol. 2012, 303:H569-H577.
16. Cai L., Kang Y.J. Oxidative stress and diabetic cardiomyopathy: a brief review. Cardiovasc. Toxicol. 2001, 1:181-193.
17. Ma Q. Role of Nrf2 in oxidative stress and toxicity. Annu. Rev. Pharmacol. Toxicol. 2013, 53:401-426.
18. Kumar S., Kain V., Sitasawad S.L. High glucose-induced Ca2+ overload and oxidative stress contribute to apoptosis of cardiac cells through mitochondrial dependent and independent pathways. Biochim. Biophys. Acta 2012, 1820:907-920.
19. Baines C.P. The cardiac mitochondrion: nexus of stress. Annu. Rev. Physiol. 2010, 72:61-80.
20. Zeng C., Zhong P., Zhao Y., Kanchana K., Zhang Y., Khan Z.A., Chakrabarti S., Wu L., Wang J., Liang G. Curcumin protects hearts from FFA-induced injury by activating Nrf2 and inactivating NF-kappaB both in vitro and in vivo. J. Mol. Cell. Cardiol. 2015, 79:1-12.
21. Rajesh M., Mukhopadhyay P., Batkai S., Patel V., Saito K., Matsumoto S., Kashiwaya Y., Horvath B., Mukhopadhyay B., Becker L., Hasko G., Liaudet L., Wink D.A., Veves A., Mechoulam R., Pacher P. Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. J. Am. Coll. Cardiol. 2010, 56:2115-2125.
22. Snell-Bergeon J.K., West N.A., Mayer-Davis E.J., Liese A.D., Marcovina S.M., Agostino R.B., Hamman R.F., Dabelea D. Inflammatory markers are increased in youth with type 1 diabetes: the SEARCH case-control study 2010.
23. Nian M., Lee P., Khaper N., Liu P. Inflammatory cytokines and postmyocardial infarction remodeling. Circ. Res. 2004, 94:1543-1553.
24. Wen H.L., Liang Z.S., Zhang R., Yang K. Anti-inflammatory effects of triptolide improve left ventricular function in a rat model of diabetic cardiomyopathy. Cardiovasc. Diabetol. 2013, 12:50.
25. Lorenzo O., Picatoste B., Ares-Carrasco S., Ramirez E., Egido J., Tunon J. Potential role of nuclear factor kappaB in diabetic cardiomyopathy. Mediat. Inflamm. 2011, 2011:652097.
26. Seddon M., Looi Y.H., Shah A.M. Oxidative stress and redox signalling in cardiac hypertrophy and heart failure. Heart 2007, 93:903-907.
27. Lorenzo O., Ramirez E., Picatoste B., Eqido J., Tunon J. Alteration of energy substrates and ROS production in diabetic cardiomyopathy. Mediat. Inflamm. 2013, 2013:461967.
28. Bugger H., Abel E.D. Molecular mechanism of diabetic cardiomyopathy. Diabetologia 2014, 57:660-671.
29. Huynh K., Bernardo B.C., McMullen J.R., Ritchie R.H. Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways. Pharmacol. Ther. 2014, 142:375-415.
30. Li B., Liu S., Miao L., Cai L. Prevention of diabetic complications by activation of Nrf2: diabetic cardiomyopathy and nephropathy. Exp. Diabetes Res. 2012, 2012:216512.
31. Leonard M.O., Kieran N.E., Howell K., Burne M.J., Varadarajan R., Dhakshinamoorthy S., Porter A.G., O'Farrelly C., Rabb H., Taylor C.T. Reoxygenation-specific activation of the antioxidant transcription factor Nrf2 mediates cytoprotective gene expression in ischemia-reperfusion injury. FASEB J. 2006, 20:2624-2626.
32. Tan Y., Ichikawa T., Li J., Si Q., Yang H., Chen X., Goldblatt C.S., Meyer C.J., Li X., Cai L. Diabetic downregulation of Nrf2 activity via ERK contributes to oxidative stress-induced insulin resistance in cardiac cells in vitro and in vivo. Diabetes 2011, 60:625-633.
33. Shi Y., Liang X.C., Zhang H., Wu Q.L., Qu L., Sun Q. Quercetin protects rat dorsal root ganglion neurons against high glucose-induced injury in vitro through Nrf-2/HO-1 activation and NF-kappaB inhibition. Acta Pharmacol. Sin. 2013, 34:1140-1148.
34. Wang Y., Sun W., Du B., Miao X., Bai Y., Xin Y., Tan Y., Cui W., Liu B., Cui T., Epstein P.N., Fu Y., Cai L. Therapeutic effect of MG-132 on diabetic cardiomyopathy is associated with its suppression of proteasomal activities: roles of Nrf2 and NF-kappaB. Am. J. Physiol. Heart Circ. Physiol. 2013, 304:H567-H578.
35. Kumar V., Kumar S., Hassan M., Wu H., Thimmulappa R.K., Kumar A., Sharma S.K., Parmar V.S., Biswal S., Malhotra S.V. Novel chalcone derivatives as potent Nrf2 activators in mice and human lung epithelial cells. J. Med. Chem. 2011, 54:4147-4159.
36. Maier H.J., Schips T.G., Wietelmann A., Kruger M., Brunner C., Sauter M., Klingel K., Bottger T., Braun T., Wirth T. Cardiomyocyte-specific IkappaB kinase (IKK)/NF-kappaB activation induces reversible inflammatory cardiomyopathy and heart failure. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:11794-11799.
37. Liu Z.W., Zhu H.T., Chen K.L., Dong X., Wei J., Qiu C., Xue J.H. Protein kinase RNA-like endoplasmic reticulum kinase (PERK) signaling pathway plays a major role in reactive oxygen species (ROS)-mediated endoplasmic reticulum stress-induced apoptosis in diabetic cardiomyopathy. Cardiovasc. Diabetol. 2013, 12:158.
38. Cai L., Kang Y.J. Cell death and diabetic cardiomyopathy. Cardiovasc. Toxicol. 2003, 3:219-228.
39. Zhang Y., Babcock S.A., Hu N., Maris J.R., Wang H., Ren J. Mitochondrial aldehyde dehydrogenase (ALDH2) protects against streptozotocin-induced diabetic cardiomyopathy: role of GSK3beta and mitochondrial function. BMC Med. 2012, 10:40.
40. El-Seweidy M.M., Sadik N.A., Shaker O.G. Role of sulfurous mineral water and sodium hydrosulfide as potent inhibitors of fibrosis in the heart of diabetic rats. Arch. Biochem. Biophys. 2011, 506:48-57.
41. Dai Q.M., Lu J., Liu N.F. Fluvastatin attenuates myocardial interstitial fibrosis and cardiac dysfunction in diabetic rats by inhibiting over-expression of connective tissue growth factor. Chin. Med. J. 2011, 124:89-94.
42. Li W., Cui M., Wei Y., Kong X., Tang L., Xu D. Inhibition of the expression of TGF-beta1 and CTGF in human mesangial cells by exendin-4, a glucagon-like peptide-1 receptor agonist. Cell. Physiol. Biochem. 2012, 30:749-757.
43. Anand P., Kunnumakkara A.B., Newman R.A., Aggarwal B.B. Bioavailability of curcumin: problems and promises. Mol. Pharm. 2007, 4:807-818.
44. Yusuf S., Dagenais G., Pogue J., Bosch J., Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 2000, 342:154-160.
45. Khaper N., Bryan S., Dhingra S., Singal R., Bajaj A., Pathak C.M., Singal P.K. Targeting the vicious inflammation-oxidative stress cycle for the management of heart failure. Antioxid. Redox Signal. 2010, 13:1033-1049.